Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.
AUTOR(ES)
Ring, H A
RESUMO
Vigabatrin is a specific gamma-aminobutyric acid transaminase inhibitor. The clinical use of this drug in the treatment of epilepsy has been sporadically linked to the development of psychosis. Using 123I-IBZM, a specific dopamine D2 receptor ligand and single photon emission tomography (SPET), one month of treatment with vigabatrin was associated with a decrease in specific binding of 123I-IBZM to D2 receptors in the left hemisphere basal ganglia. This change may provide one explanation for the development of psychosis in vulnerable patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1015097Documentos Relacionados
- Class I histocompatibility antigens and insulin receptors: evidence for interactions.
- Characterization of glial trkB receptors: differential response to injury in the central and peripheral nervous systems.
- Effect of vigabatrin (gamma-vinyl GABA) on amino acid levels in CSF of epileptic patients.
- Human striatal dopamine receptors are organized in compartments.
- Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
